Association of lipid-lowering drugs with osteoarthritis outcomes from a drug-target Mendelian randomization study
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0293960 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Weiwei Ma und 3 weiteren Autor:innen. Beteiligte Einrichtung: Affiliated Hospital of Hubei University of Chinese Medicine, Wuhan, China. Hauptthemen laut MEDLINE: Osteoarthritis, Knee. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Osteoarthritis (OA), a prevalent musculoskeletal disorder, has been suggested to have a potential association with metabolic syndrome, particularly lipid metabolism. Studies exploring the effects of lipid-lowering drugs on OA have yielded conflicting results.
Objective
This study employed a drug-targeted Mendelian randomization approach to investigate the association between genetically predicted lipid-modulating effects of commonly targeted lipid-lowering agents and the risk of OA, with the aim of providing a theoretical foundation for the use of lipid-lowering drugs in OA treatment.
Methods
Employing Mendelian randomization (MR) analysis, we examined the potential causal relationship between lipid-lowering drugs and OA. Genetic variants associated with LDL cholesterol levels were selected from the GWAS summary data, and a series of statistical analyses, including inverse-variance weighted (IVW), weighted median (WM), and MR-Egger, were performed to estimate causal effects.
Results
We observed significant associations between genetically proxied lipid-lowering drug targets and OA risk. Notably, HMGCR-mediated LDL cholesterol showed an association with overall OA of the hip or knee (OR = 0.865, 95%CI: 0.762 to 0.983, p = 0.026, q = 0.07) and knee osteoarthritis specifically (OR = 0.746, 95%CI: 0.639 to 0.871, p = 2.180×10 −4 , q = 0.004). PCSK9-mediated LDL cholesterol also demonstrated an association with OA of the hip or knee (OR = 0.915, 95%CI: 0.847 to 0.988, p = 0.023, q = 0.07) and knee osteoarthritis (OR = 0.901, 95%CI: 0.821 to 0.990, p = 0.03, q = 0.07). NPC1L1-mediated LDL cholesterol showed a positive association with OA of the hip or knee (OR = 1.460, 95%CI: 1.127 to 1.890, p = 0.004, q = 0.033). Furthermore, LDLR-mediated LDL cholesterol demonstrated an association with OA of the hip or knee (OR = 0.882, 95%CI: 0.788 to 0.988, p = 0.03, q = 0.07) and hip osteoarthritis (OR = 0.867, 95%CI: 0.769 to 0.978, p = 0.02, q = 0.07).
Conclusions
These findings provide preliminary evidence for the potential therapeutic use of lipid-lowering drugs in OA treatment. Further investigation is needed to validate these findings and explore the precise mechanisms underlying the observed associations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Affiliated Hospital of Hubei University of Chinese Medicine, Wuhan, China.
- Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, China.
- Hubei Provincial Institute of Traditional Chinese Medicine Wuhan, China.
- The Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
- School of Acupuncture-Moxibustion and Orthopedics, Hubei University of Chinese Medicine, Wuhan, China.
ORCID-Profile: Weiwei Ma, Yong Xiong
Zitieren
APA
Ma, W., Chen, H., Zhang, Z., & Xiong, Y. (2024). Association of lipid-lowering drugs with osteoarthritis outcomes from a drug-target Mendelian randomization study. PLOS ONE. https://doi.org/10.1371/journal.pone.0293960
Vancouver
Ma W, Chen H, Zhang Z, Xiong Y. Association of lipid-lowering drugs with osteoarthritis outcomes from a drug-target Mendelian randomization study. PLOS ONE. 2024. doi:10.1371/journal.pone.0293960
BibTeX
@article{Ma2024,
author = {Ma, Weiwei and Chen, Honggu and Zhang, Zhiwen and Xiong, Yong},
title = {Association of lipid-lowering drugs with osteoarthritis outcomes from a drug-target Mendelian randomization study},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0293960}
}
EUVIMED